Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The passive transfer of maternal immunity is responsible for keeping all mammalian species alive. The process of evolution developed effective mechanisms for the passive transfer of both systemic and mucosal immunity from the mother to her offspring. Experimental passive transfer of systemic immunity via serum antibody is well established, but the experimental passive transfer of mucosal immunity has only recently been accomplished. This chapter addresses the contributions of both natural and experimental mechanisms to the study of passive immunization.

**NATURAL PASSIVE IMMUNIZATION**

**Systemic immunity**
The transfer of systemic immunity (IgG) from mother to offspring occurs prenatally via the placenta or yolk sac and after birth via the colostrum. Species vary in the contribution each route makes to the transfer of immunity (Waldman and Strober, 1969) and can be grouped into three categories: prenatal transfer only, combined prenatal and postnatal transfer, and postnatal transfer only.

**Prenatal transfer only**
This group includes primates, rabbits, and guinea pigs. Transport of IgG in primates occurs almost exclusively through the placenta. IgG transfer occurs via a receptor-mediated transcytosis across the syncytiotrophoblast and a transcellular pathway through the fetal endothelium (Leach et al., 1990). Human placental transfer of protective IgG antibodies to a number of pathogens, including hepatitis B (Hockel and Kaufman, 1986), measles (Lennon and Black, 1986), and group B streptococcus (Baker et al., 1988), has been reported. This process suggests an effective method of neonatal immunization, i.e., immunization of the pregnant mother in order to protect the neonate. Prenatal transfer of IgG in the rabbit occurs via the yolk sac, and in the guinea pig, via both the yolk sac and fetal gut (Waldman and Strober, 1969).

**Combined prenatal and postnatal transfer**
This group includes rats, mice, cats, and dogs. Prenatal transmission occurs via the yolk sac/placenta and the fetal gut in the rat (Waldman and Strober, 1969). IgG is bound rapidly to receptors on the surface of the yolk sac membrane (Mucchielli et al., 1983), is endocytosed in clathrin-coated vesicles, and, early in gestation, is stored in subapical vacuoles. By late gestation, the antibody has been hydrolyzed or transferred to fetal capillaries (Jollie, 1985). Prenatal transmission in mice occurs by a similar mechanism (Gardner, 1976).

Although placental transfer occurs, studies in rodents have shown that most transport of antibody occurs postnatally from colostrum or milk (Arango-Jaramillo et al., 1988; Barthold et al., 1988; Heiman and Weisman, 1989; Kohl and Loo, 1984; Nejami et al., 1975; Oda et al., 1983) over a period of 10 to 21 days, depending on the species. There is a gradual decrease in transmission over the last 3 days (Waldman and Strober, 1969), and transmission is limited to antibodies of the IgG class (Appleby and Catty, 1983; Hammerberg et al., 1977). Transport is a receptor-mediated process (Simister and Rees, 1983). In rats, the receptor (FcRn) is found in enterocytes of the proximal intestine during the early postnatal period but is absent after weaning (Jakoi et al., 1985). FcRn is specific for IgG and its Fc fragment and consists of two similar polypeptides of 48,000 to 52,000 daltons (p51) in association with β2 microglobulin (Jakoi et al., 1985; Simister and Mostov, 1989). The Fc binding subunit (p51) has three extracellular domains and a transmembrane region that are all homologous to the corresponding domains of class I major histocompatibility complex (MHC) antigens (Simister and Mostov, 1989). Junghans and Anderson (1996) have shown that disruption of the FcRn in knock-out mice also destroys the receptor (FcRp) necessary for the prolonged half-life of serum IgG in adults, suggesting that the same receptor protein that mediates transient IgG transport across the neonatal gut functions as the FcRp throughout life.
Postnatal transfer only
This group includes ruminants (cattle, sheep, goats), horses, and pigs (reviewed in Tizzard, 1987). Transport of colostral proteins from the lumen of the ileum in ruminants is largely nonspecific, but in the horse and the pig, IgG and IgM are preferentially absorbed. Proteins are actively taken up by epithelial cells through pinocytosis and passed through these cells into the lacteals and intestinal capillaries (Tizzard, 1987). Intestinal absorption occurs for only the first 24 to 48 hours after birth. Following this, the “open gut” closes down, and no further transfer from milk or colostrum occurs (Ellis et al., 1985), et al., 1972), providing extra antibody stability in mucosal acid (Kenny et al., 1984; Tizzard, 1987; Waldman and Strober, 1969). Newborn piglets have also been shown to absorb colostral lymphoid cells during this period (Tuboly et al., 1988). It is unclear whether these cells are fully functional and capable of immune processes such as the transfer of delayed-type hypersensitivity (DTH).

Absorption of colostral immunoglobulin is normally extremely effective, supplying the newborn with serum immunoglobulin (particularly IgG) at a level approaching that found in adults (Tizzard, 1987); however, failure of passive transfer (FPT) can occur and, when it does, can pose a considerable problem in animal husbandry. About 25% of newborn foals fail to obtain sufficient quantities of immunoglobulin (McGuire et al., 1975; Tizzard, 1987). In the McGuire study (1975), two of nine foals affected by FPT died of infections within a few days of birth, and five of the remaining seven developed nonfatal respiratory infections between 2 and 5 weeks of age. McGuire et al. (1976) also reported FPT in calves, finding that 85% of calves less than 3 weeks old dying from infectious diseases have significant hypogammaglobulinemia. Although adequate methods to diagnose and treat FPT are available (Bertone et al., 1988; Tizzard, 1987), the phenomenon remains a significant veterinary problem.

Mucosal immunity
Mother's milk provides passive protection of the mucosal surfaces it contacts. This protection may be mediated either by specific immunity or by nonspecific factors found in milk, such as lactoferrin, lysozyme, fatty acids, and complement (reviewed in Goldman et al., 1985). The antibody composition of milk differs from that of colostrum (Tizzard, 1987), and the class of protective antibody in milk varies with the species and the route of immunization of the mother. With the exception of IgG in rodents, these protective antibodies are not systemically absorbed by the suckling offspring, but exert their protective effect locally by neutralizing viruses or virulence factors and by binding to microbial pathogens and preventing their attachment to the mucosal surface (Goldman et al., 1985). Secretory IgA (S-IgA) is especially suited to this protective role, because secretory component enhances its resistance to proteolytic enzymes and gastric acid (Kenny et al., 1967; Lindh, 1975; Tomasi, 1970; Zikan et al., 1972), providing extra antibody stability in mucosal secretions.

Milk antibody in rodents
Rodents have been a popular model for the study of passive transfer of maternal immunity via milk; however, this class of animals has a major drawback as a model for passive mucosal immunity. Both rats and mice can actively transport IgG from the gut into the serum for approximately 2 weeks (see Combined Prenatal and Postnatal Transfer earlier in this chapter); thus, observed protection could be due either to antibody in the milk bathing the mucosal surfaces or to maternal antibody being transported into the serum and secretions of the offspring. This caveat should be kept in mind during evaluation of the many reports of milk-borne protection in these species. Three rodent models in which protection of mucosal surfaces is due to milk-borne, not serum-derived, antibody are described next.

The predominant immunoglobulin in mouse milk is IgG, although significant levels of IgA can also be present (Ijaz et al., 1987). Protection of infant mice from colonization with Campylobacter jejuni can be achieved by the consumption of immune milk at and after the time of bacterial challenge. Infant mice were not protected by prior consumption of colostrum, showing that milk antibody was required in the gut lumen for protection to be observed (Abmiku and Dolby, 1987). A similar requirement for antibodies active at the intestinal cell surface in immunity to primate rotavirus SA-11 was reported by Offit and Clark (1985).

Protection of rats against dental caries by milk can be due to either IgG or S-IgA antibodies, depending on the route of maternal immunization. Rat dams immunized intravenously with heat-killed Streptococcus mutans developed IgG antibodies in their colostrum, milk, and serum. Their offspring demonstrated significant protection against S. mutans-induced caries formation. Rat dams locally injected in the region of the mammary gland with heat-killed S. mutans or fed formalin-killed S. mutans developed S-IgA antibodies in their colostrum and milk. Their offspring were also protected against caries formation (Michalek and McGhee, 1977). Caries protection in suckling rats could theoretically be due to bathing of mucosal surfaces and/or leakage of antibody into the saliva from the serum. Nonimmune adult rats can be protected from S. mutans-induced caries by feeding by lyophilized immune bovine milk or on immune bovine whey containing specific IgG (Michalek et al., 1978a; Michalek et al., 1987). Since adult rats are unable to transport orally administered IgG into their serum, protection must be from milk-derived antibodies bathing the oral cavity.

Milk antibody in ungulates
In ruminants (sheep, cattle, goats), the predominant antibody in both colostrum and milk is IgG. The predominant antibody in the colostrum of pigs and horses is also IgG, but as lactation progresses and colostrum becomes milk, IgA predominates (Tizzard, 1987). Protection can be mediated by either antibody class. While bathing of the mucosal surfaces by milk-derived antibodies can provide passive immunity to some pathogens, the high rate of infections in FPT...
foals and calves shows that milk (mucosal immunity) alone cannot provide complete protection to neonates.

In cattle and pigs, passive immunity against enteric infections with viruses such as rotaviruses and coronaviruses (transmissible gastroenteritis, or TGE) is dependent on the continual presence in the gut lumen of a protective level of specific antibodies (Crouch, 1985). Passive immunity against intestinal infection with the TGE virus is generally more complete in piglets ingesting IgA antibodies than in those ingesting IgG antibodies, although both classes of antibody are protective. The class of antibody present in calf scours (neonatal bovine colibacillosis caused by Escherichia coli) correlates with the level of specific IgA antibody in the mother’s milk (Wilson and Jutila, 1976).

**Milk antibody in primates**

In primates, IgA is the predominant immunoglobulin in both colostrum and milk (Tizzard, 1987). Both lysozyme and S-IgA in human milk remain functional in the digestive tract of the early infant (Eschenburg et al., 1990). Human milk has been shown to contain S-IgA antibodies to at least five viral and nine bacterial pathogens, as well as to fungi, parasites, and food antigens (Goldman et al., 1985). Mucosal immunity to rotavirus, for example, was shown to be transferred to the infant by the S-IgA in milk; there was a positive correlation between titers of secretory component (SC) in the mother’s milk and the infant’s feces vs. virus-specific IgA in the infant’s fecal samples (Rahman et al., 1987). In addition to providing passive mucosal immunity, human breast milk also stimulates the early local production of S-IgA in the urinary and gastrointestinal tracts, thereby accelerating the development of an active local host defense in the infant (Koutras and Vigorita, 1989; Prentice, 1987).

**Experimental Passive Immunization**

Since the original demonstration of transfer of immunity by the injection of serum (von Behring and Kitasato, 1890), passive transfer of humoral immunity has been intensively investigated. The use of specific serum antibody (IgG) to transfer protection to nonimmune individuals is now standard medical practice in, for example, the postexposure prophylaxis for rabies and tetanus and the treatment of snakebite (Arnold, 1982; Centers for Disease Control, 1991a, 1991b), while intravenous immunoglobulin (IVIg) treatment has been shown to lower the incidence of pneumonia in patients with common variable immunodeficiency (Busse et al., 2002).

Local immunity has been correlated with the level of IgA antibody in various secretions (reviewed in Renegar and Small, 1993); however, direct demonstration of the mediation of local immunity by injected IgA could not occur until specific transport of passively administered IgA had been confirmed.

**Transport of passively administered IgA to mucosal surfaces**

**Gastrointestinal tract**

In rabbits, rats, and mice, polymeric IgA (pIgA) is efficiently transported from the circulation into the bile via the liver (Delacroix et al., 1985; Koertge and Butler, 1986a; Mestecky and McGhee, 1987; Orlans et al., 1978, 1983). These species express pIg receptor (pIgR) on their hepatocytes (Socken et al., 1979) and, in addition, have pIgA as the primary molecular form in their serum (Heremans, 1974; Vaerman, 1973). Serum IgA is also efficiently transported into bile in cattle (Butler et al., 1986). In fact, most IgA in ruminant bile may be of serum origin.

Transport of serum IgA into bile in humans has been reported (Delacroix et al., 1982; Dooley et al., 1982), although IgA transport is about 50-fold less efficient than in rats and rabbits. The human biliary IgA level is approximately 20% of the human serum IgA level and, under physiologic conditions, only 50% of human biliary IgA is derived from the serum (Vaerman and Delacroix, 1984). Even though transport is possible, passively administered IgA does not reach high levels in human bile. In one study, less than 3% of intravenously injected radio labeled pIgA was found in human bile at 24 hours (Vaerman and Delacroix, 1984).

**Saliva**

Serum pIgA can be transported into saliva in dogs (Montgomery et al., 1977), monkeys (Challacombe et al., 1978), mice (Falero-Diaz et al., 2000), and humans (Delacroix et al., 1982; Kubagawa et al., 1987). In humans the amount of IgA acquired from the plasma is low (only 2%) compared with the amount acquired from local production (Delacroix et al., 1982). Transfer of pIgA from the plasma into canine or murine saliva is a selective process requiring the pIgR (Montgomery et al., 1987; Falero-Diaz et al., 2000), while transport into oral fluids in monkeys appears to be by leakage from the plasma into the crevicular spaces surrounding the deciduous molars (Challacombe et al., 1978).

**Milk**

In sheep, active transport of IgA from the circulation into milk seems likely (Sheldrake et al., 1984); however, studies on the transport of IgA into murine milk have produced conflicting results. Using radiolabeled IgA, Halsey et al. (1983) demonstrated that in the mouse, IgA can be transported from the circulation into milk during early lactation. Other investigators (Koertge and Butler, 1986b; Russell et al., 1982), using assays based on antibody-binding activity, were unable to show transport of IgA into murine milk. Using radiolabeled IgA, Koertge and Butler (1986b) were able to show that the IgA present in milk was degraded and suggested that the previous study (Halsey et al., 1983) detected only IgA fragments that had been transudated into the milk from the serum and not specifically transported IgA. Passively administered IgA is not transported into the milk of rats (Dahlgren et al., 1981; Koertge and Butler, 1986b).
**Respiratory tract**

Only a limited number of studies on the transport of antibodies into respiratory secretions have been reported, but the results have shown that selective transport of passively administered serum IgA into the respiratory tract is possible in sheep and mice. Because of their importance as background to the experiments demonstrating the passive transfer of local immunity by IgA, these respiratory transport studies will be addressed in more detail.

**Sheep.** Using the intravenous injection of radioiodinated ovine immunoglobulin, Scicchitano et al. (1984) showed that 35% of the IgA in the mediastinal lymph of sheep is plasma-derived. It was further demonstrated (Scicchitano et al., 1986) by the simultaneous intravenous injection of radiolabeled IgA and radiolabeled IgG1 or IgG2 that IgA is selectively transported into ovine respiratory secretions. Transport of IgA was approximately 4.5 times greater than transport of IgG2, and the transported IgA was intact in the secretions. Biological activity of the transported IgA was not determined.

**Mice.** Mazanec et al. (1989) found that 4 to 5 hours after the intravenous injection of radiolabeled monomeric or polymeric IgA anti-Sendai virus monoclonal antibodies into mice, transport of pIgA into nasal secretions was three to seven times more efficient than transport of monomeric IgA (mIgA), while pIgA transport into bronchoalveolar lavages was only one to three times more efficient. This difference may reflect an increased contribution of serum antibody due to the transudation of IgG into alveolar fluids. Transport of pIgA into the gut was four to five times more efficient than the transport of mIgA, as expected. The agreement of the nasal secretion and gut transport indices suggests that transport at these two sites could occur by a similar mechanism. The investigators were unable to demonstrate the presence of functionally intact pIgA in the upper respiratory tract.

The pIgA transported into murine nasal secretions in the studies reported by Renegar and Small (1991a) was, in contrast, functionally intact. To avoid problems associated with the quantification of intact vs. degraded radiolabeled IgA in secretions (described by Koertge and Butler, 1986b), this study used an anti-influenza enzyme-linked immunosorbent assay (ELISA) to evaluate the transport of monomeric or polymeric IgA or IgG monoclonal anti-influenza antibodies into nasal secretions of mice. Nonimmune mice were injected intravenously with influenza-specific mIgA, pIgA, or IgG, and sacrificed at varying times between 2 and 24 hours postinjection. The peak nasal wash pIgA titer was reached 4 hours after antibody injection and was approximately 20 times greater than the nasal wash titer of either monomeric immunoglobulin.

To determine whether pIgA was selectively transported relative to IgG, the investigators injected a mixture of the two monoclonals intravenously into nonimmune mice and calculated a selective transport index for nasal antibody for each mouse. Twenty-nine of the 31 mice studied showed selective transport of IgA relative to IgG. Using a similar model, Steinmetz et al. (1994) determined that passively administered monoclonal pIgA isotype-switch variants, generated from IgG hybridomas producing antibodies specific for bacterial respiratory tract pathogens, were selectively transported relative to IgG into both the upper and lower respiratory tract secretions of mice. In agreement with the results of Renegar and Small (1991a), Falero-Díaz et al. (2000) showed that, in mice, parenterally administered (either intravenously or by “backpack” tumor growth) monoclonal pIgA acquired SC as it was transported from the serum into nasal or vaginal secretions or into the bile, while similarly administered IgG did not, suggesting specific transport of the IgA but not the IgG. In contrast to Steinmetz et al. (1994) but in agreement with Mazanec et al. (1989), the Falero-Díaz group found efficient transmission of IgG but not of pIgA into the lungs of mice. In fact, they found that topical administration under light anesthesia of IgA as nosedrops was a more effective method for the delivery of IgA into the lungs than either parenteral method.

Thus, transport of serum IgA into nasal secretions is possible in some species. The relevance of this transport to the passive transfer of local immunity will be addressed in the following section.

**Protection of mucosal surfaces by passively administered antibodies**

Studies of the passive transfer of local immunity can be classified into two categories. In the first are those studies in which the antibody is introduced into the local secretions exogenously or mixed with the target pathogen prior to host challenge. The second category includes those studies in which systemically administered pIgA must be physiologically transported by a pIgR-mediated mechanism to its site of activity.

**Exogenously administered antibody**

The studies in this category have investigated the role of IgA in mucosal immunity by feeding antibody or instilling it intranasally or intravaginally and then challenging, or by administering antibody-pathogen mixtures intranasally.

**Oral antibody.** Offit and Clark (1985) demonstrated the ability of milk-derived IgG and IgA to protect the murine intestine from infection with primate rotavirus SA-11. Suckling mice were protected by milk from dams that had been orally immunized with SA-11 virus. This protective activity was detected in both the IgG and IgA fractions, but the IgA fraction was more potent in vivo than the IgG fraction. In newborn mice from immune dams foster-nursed on mice that had been orally immunized with SA-11 virus. This protective activity was detected in both the IgG and IgA fractions, but the IgA fraction was more potent in vivo than the IgG fraction. In newborn mice from immune dams foster-nursed on milk from seronegative dams, the presence of circulating systemic antibodies in high titer did not protect against SA-11 viral infection. Thus, the specific antibody had to be present in the gut lumen to protect the intestinal cell surface from viral infection, and S-IgA could mediate this protection.

Enriquez and Riggs (1998) developed a series of dimeric IgA monoclonal antibodies directed toward the sporozoite antigen P23 of Cryptosporidium parvum, an important diarrhea-causing protozoan parasite. When administered orally prior to parasitic challenge, these antibodies were able to...
reduce the number of intestinal parasites in infected neonatal mice by up to 70%. These results extend the work of Albert et al. (1994), who successfully treated cryptosporidiosis in nude mice by the oral administration of rat bile containing C. parvum–specific IgA, while Czinn et al. (1993) protected germ-free mice from infection by Helicobacter felis by incubating the bacteria with specific IgA antibody prior to oral administration. The protective antibody was later shown to be directed against urease (Blanchard et al., 1995).

A significant number of systemic infections in the human neonate originate from the gastrointestinal tract, especially in premature infants with immature gut barriers. Maxson et al. (1996) fed rabbit pups human S-IgA via intra gastric gavage, then challenged them with E. coli K100. IgA-treated pups had significantly fewer bacteria translocated from the gut to the liver, spleen, and mesenteric lymph nodes. This neonatal rabbit model provides the first demonstration of control of bacterial translocation by IgA and suggests that oral supplementation with IgA may be beneficial for patients at risk for gut-origin sepsis.

**Intranasal antibody.** A number of studies have shown that exogenously administered IgA can protect against intranasal challenge with a pathogen. Bessen and Fischetti (1988) showed that S-IgA given by the intranasal route protected mice against streptococcal infection. Live streptococci were mixed with affinity-purified human salivary S-IgA or serum IgG antibodies directed toward the streptococcal M6 protein. The mixture was administered intranasally to mice. The S-IgA antibody protected against streptococcal infection, while the serum antibody had no effect. This study suggested that S-IgA alone is capable of protecting the mucosa against bacterial invasion.

Mazanec et al. (1987) demonstrated that IgA can protect mucosal surfaces against viral infection. Ascites containing IgA anti-Sendai virus monoclonal antibody was administered intranasally to lightly anesthetized mice before and after the mice were challenged intranasally with live virus. Three days later, mice were sacrificed and lung viral titers were determined. Animals treated with the specific monoclonal antibody were protected against viral infection. Further work from the same laboratory showed that local immunity to Sendai virus can also be mediated by intranasally administered IgG (Mazanec et al., 1990). Tamura et al. (1991) purified anti-influenza S-IgA antibodies from the respiratory tracts of mice immunized with influenza hemagglutinin molecules. This IgA, when given intranasally, protected nonimmune mice from influenza infection. Protection was observed up to 3 days after antibody administration, was proportional to the amount of IgA administered, and was observed at IgA doses equivalent to naturally occurring antibody titers.

**Intravaginal antibody.** Zeitlin et al. (1998) were able to protect the mouse vagina from infection with herpes simplex virus 2 (HSV-2) by the topical administration of either IgG or IgA monoclonal antibody directed against glycoprotein D of HSV-2.

These studies show that topically administered local IgA or IgG can protect against viral or bacterial infection of the mucosa. They do not show that physiologically transported (secretory) IgA or serum-derived IgG actually does so. For that demonstration, antibody must be administered parenterally and transported into the mucosal secretions by a physiologic mechanism. The studies presented in the next section satisfy that criterion.

**Systemically administered antibody**

The definitive studies in this category have involved the respiratory and gastrointestinal tracts, although passive transfer of uterine immunity by pIgA has also been observed (Renegar and Small, 1993; Cotter et al. 1995; Pal et al. 1997), and Leher et al. (1999) demonstrated the protection of Chinese hamsters and pigs against Acanthamoeba castellanii–mediated keratitis by intraperitoneally administered antigen-specific monoclonal IgA. Work with the respiratory and gastrointestinal tracts will be presented in more detail.

**Respiratory tract.** The respiratory tract can be separated into an upper region (nose and trachea) and a lower region (lungs and bronchi) with immunity at each site involving different elements of the immune system. Numerous studies have shown that passively administered serum anti-influenza antibody (IgG) can prevent lethal viral pneumonia (Barber and Small, 1978; Kris et al., 1988; Loosli et al., 1953; Ramphal et al., 1979; Palladino et al., 1995). Serum antibody, however, does not prevent influenza infection of the upper respiratory tract (Barber and Small, 1978; Kris et al., 1988; Ramphal et al., 1979), Protection of the nose correlates with an increased nasal secretion IgA antibody level (reviewed in Renegar and Small, 1993), making influenza an excellent model in which to investigate the hypothesis that nasal immunity is mediated by S-IgA.

The first demonstration of the passive transfer of local immunity by physiologically transported S-IgA was reported by Renegar and Small (1991a) in the murine influenza model. They showed, as described above, that intravenously administered pIgA is transported into nasal secretions. To determine whether intravenously administered pIgA anti-influenza monoclonal antibody could mediate protection against local influenza virus challenge, passively immunized mice were challenged intranasally while awake with influenza virus. Twenty-four hours later the mice were sacrificed and the amount of virus shed in their nasal secretions was determined. Of the 24 saline-injected control mice, 23 shed virus into the nasal secretions, while only 5 of the 25 pIgA injected mice shed virus, and those 5 that did shed virus had a low titer. The observed protection was significant ($p < 0.001$). Passive immunization with influenza-specific pIgA therefore conferred complete protection against viral infection in 80% of the mice and partial protection in the remaining 20%. Serum IgG was found to confer only limited protection against nasal influenza infection (minimal reduction in viral shedding [$p < 0.02$], with only one of eight mice intravenously injected with influenza-specific IgG not shedding virus [$p < 0.5$]).

The passive protection studies showed that IgA can mediate local immunity. To confirm that IgA is the mediator of...
local immunity, mice passively immunized with pIgA were given nose drops of anti-IgA antibody 10 minutes before and 6 hours after they were challenged intranasally with influenza virus suspended in anti-IgA antiserum. Anti-IgA treatment abrogated IgA-mediated protection in the passively immunized mice (Renegar and Small, 1991a). To show that the passive transfer of local immunity by IgA was a reflection of the natural situation, the abrogation technique was extended to mice convalescent from influenza infection (Renegar and Small, 1991b). Nonimmune mice and convalescent mice, i.e., mice that had recovered from an influenza virus infection 4 to 6 weeks earlier and were therefore naturally immune, were treated intranasally with antiserum to IgA or IgG or with a mixture of antisera to IgG and IgM and then challenged while awake with influenza virus mixed with antisera. Intranasal administration of antiserum was continued at intervals for 24 hours. One day after viral challenge, the mice were killed and their nasal washes were assayed for virus shedding. Nonimmune mice all became infected, regardless of whether the virus was administered in saline, normal rabbit serum, or anti-immunoglobulin antiserum. Convalescent mice, as expected, were protected from viral infection. Administration of influenza virus in either anti-IgG or a mixture of anti-IgG and anti-IgM antisera did not affect protection, i.e., the convalescent mice were still immune. Administration of virus in anti-IgA antiserum, however, abrogated convalescent immunity. These results demonstrate that IgA is a major mediator of murine nasal immunity and suggest that passive immunization mimics the role S-IgA plays in natural immunity. These observations were extended by the work of Philipon et al. (1995). Using the backpack method of monoclonal antibody administration, they demonstrated that monoclonal IgA antibody directed against Shigella flexneri serotype 5a lipopolysaccharide protects mice against intranasal challenge with S. flexneri. Mbawuicke et al. (1999), however, have used the IgA knockout mouse model to challenge these findings. Mice unable to produce IgA antibodies were able to generate a protective anti-influenza response and to transport passively administered anti-influenza antibodies into both the upper and lower respiratory tracts. Knockout mice, however, may not be the best model in which to study the role of IgA in nasal immunity, because, with the congenital loss of IgA, production of other classes of antibody such as IgG may be increased as a compensatory mechanism. The data of Mbawuicke et al. suggest that this may be the case, as influenza-specific IgG levels were higher in immune knockout mice than in normal mice, and an altered IgG subclass distribution in response to influenza infection was observed (Harriman et al., 1999; Zhang et al., 2002). Furthermore, perturbation of mucosal IgA transport in the pIgR knockout mouse (Johansen et al., 1999) led to increased mucosal leakiness and increased serum total IgG levels, indicating a defect in the mucosal barriers. It is known (Renegar et al., 2004) that at a dose high enough to give a serum titer seven times the normal anti-influenza IgG titer of convalescent mice, intravenously administered influenza-specific IgG can lower or eliminate the nasal secretion viral load; however, scanning electron microscopy has revealed that even this high IgG dose does not prevent infection of the nasal epithelium. Thus, the lowered nasal secretion viral titers reported in IgG-protected mice may be due to neutralization of newly replicated virus by serum antibody leaking through the virally damaged epithelium. Furthermore, the serum anti-influenza IgG antibody titer has to be several times higher than that normally observed for the IgG effect to be observed, because serum antibody at a level comparable to that of normal convalescent mice neither depresses viral shedding nor prevents viral pathology in the nasal epithelium.

Since the publication of the IgA knockout mouse work, a model has been reported in which mucosal IgA levels are depressed in genetically normal mice while serum IgG remains unaffected (Renegar et al., 2001a, 2001b). In mice, total parenteral nutrition (TPN) depressed nasal mucosal immunity to influenza virus, resulting in increased viral shedding from the noses of TPN-fed immune mice (Fig. 46.1A). In these mice, nasal influenza–specific IgA was severely depressed (Fig. 46.1B), while the serum anti-influenza IgG titer was unaffected (Fig. 46.1C). Thus, in genetically normal ICR mice, serum IgG alone is not capable of preventing viral infection of the nose. Protection could be restored by the intravenous administration of influenza-specific pIgA monoclonal antibody (Fig. 46.1D). This work strongly suggests that IgA is required for the prevention of influenza virus infection in the noses of normal mice.

Gastrointestinal tract. Additional evidence that S-IgA is the mediator of local immunity comes from studies of the gastrointestinal tract. Polymeric IgA hybridomas against Vibrio cholerae were generated and the resulting monoclonal antibodies were used to determine whether IgA can mediate immunity toward a bacterial pathogen in the gut (Winner et al., 1991). The investigators selected a clone that produced dimeric monoclonal IgA antibodies directed against an Ogawa-specific lipopolysaccharide carbohydrate antigen exposed on the bacterial surface. These antibodies were able to cross-link bacterial organisms in vitro, suggesting that they might be effective in preventing mucosal colonization by the pathogen in vivo. To provide continuous physiologic (i.e., secretory-component–mediated) transport of specific antibody into the gut, hybridoma cells were injected subcutaneously into the backs of adult BALB/c mice. These “backpack” tumors released monoclonal IgA into the circulation, and the plasma IgA was transported into the gut lumen. Neonatal mice bearing these backpack tumors survived challenge with V. cholerae, while neonatal mice bearing backpack tumors of unrelated IgA hybridomas and non-tumor-bearing neonatal mice died. This ingenious model provided the first evidence that S-IgA alone can mediate mucosal immunity to a bacterial pathogen. Michetti et al. (1992) have since demonstrated that pathogen-specific monoclonal S-IgA can protect mice from infection by Salmonella typhimurium following oral challenge.

The backpack model has also been used to treat rotavirus infections of the gastrointestinal tract of mice (Burns et al.,
Non-neutralizing monoclonal IgA antibodies directed against VP6, a major inner capsid viral protein, were capable of both preventing primary and resolving chronic murine rotavirus infections. These findings are consistent with the hypothesis that in vivo intracellular viral inactivation by pIgA during transcytosis is a mechanism of host defense against rotavirus infection.

**CLINICAL APPLICATIONS**

The general approach of passive parenteral transfer of mucosal immunity has proven to be a useful research tool for determining the role of S-IgA in protection against various mucosal pathogens. The possibility of therapy by passively administered IgA antibody is more problematic. Passive protection by injection is highly speculative because of both the questionable efficiency of transport to the targeted mucosal surface and the potential adverse effects of intravenous IgA antibody. Serum IgA has been associated with both decreased complement activation (Russell et al., 1989) and decreased immune lysis (Griffiss and Goroff, 1983). Systematically administered pIgA may also be suppressive of both specific humoral and cellular responses (Renger and Small, unpublished observations). A more thorough knowledge of the role IgA can play in regulating the immune response is needed before intravenous passive mucosal immunization can become an acceptable means of therapy in man; however, the direct oral or respiratory application of antibodies to the mucosal surfaces is both practical and acceptable.

Control of dental carries is a feasible target for topical IgA administration. One study is particularly intriguing. Ma et al. (1998) generated a monoclonal secretory antibody in transgenic plants and showed that it survived up to 3 days in the human oral cavity; furthermore, this antibody afforded specific protection against oral streptococcal colonization for at least 4 months.

The literature contains a number of reports of the passive transfer of immunity against gastrointestinal pathogens in humans (reviewed in Bogstedt et al., 1996, and in Hammarström et al. 1994). This immunity has been provided by the oral administration of purified human IgG or serum IgA and has been used as both a prophylactic and a therapeutic measure against rotavirus infection in children (Barnes et al. 1982; Guarino et al., 1994) and as a therapeutic measure against bacterial diarrheas (Tjellstrom et al., 1993; Hammarström et al., 1993). Oral administration of bovine antibodies has also been used successfully in the prophylaxis of bacterial and rotaviral diarrheas in man and in the treatment of human rotavirus infections (Bogstedt et al., 1996; Mitra et al., 1995). Chicken egg yolk antibody (IgY) protects calves against bovine rotavirus (Kuroki et al., 1994).

Provision of passive immunity by the intranasal administration of antibodies has been reported in both human and...
nonhuman primate models. Human gamma globulin admin-
istered intranasally showed promise in challenge experiments
with influenza or coxsackie A-21 viruses (Fruchtman et al.,
1972; Buthala et al., 1970). IgA antibodies (IgAbulin), given
as a nasal spray to the Swedish ski team during the Albertville
Winter Olympic Games, significantly reduced the level of
upper respiratory tract infections (Hammarström et al.,
1994); however, IgAbulin treatment had no effect on the fre-
quency of upper respiratory tract symptoms in elite canoeists
studied during hard and moderate training regimens (Lindberg
and Berglund, 1996). IgAbulin nosedrop treat-
ment of variable immunodeficiency patients who were
chronic nasopharyngeal carriers of nonencapsulated
Haemophilus influenzae eliminated the carrier state in 2 of 5
patients and alleviated coughing in all 5 (Lindberg
and Berglund, 1996). IgAbulin nosedrops elimi-
nated the carrier state in 2 of 5 Haemophilus influenzae
chronic nasopharyngeal carriers of nonencapsulated
ment of variable immunodeficiency patients who were
intranasal instillation of antibodies is feasible and may pro-
to be effective in the management of immunosuppressed
Intranasal administration of specific antibodies may prove
to be even more exciting. Weltzin et al. (1996) treated rhesus
monkeys with nose drops containing mouse monoclonal IgA
antibody against respiratory syncytial virus (RSV). Treated
monkeys had reduced viral shedding in the nose, throat, and
lungs and developed neutralizing serum antibody to RSV,
even in the absence of detectable viral replication. RSV is a
major cause of lower respiratory tract disease in infants and
young children, producing severe disease in children with
underlying conditions of the heart or lungs. These results
suggest that prophylactic administration of monoclonal anti-
body nose drops could provide effective protection against
RSV infection in at-risk human infants.

REFERENCES
Abimiku, A.G., and Dolby, J.M. (1987). The mechanism of protection
of infant mice from intestinal colonization with Campylobacter
jejuni. J. Med. Microbiol. 23, 339–344.
Albert, M.M., Rusnak, J., Luther, M.F., and Graybill, J.R. (1994).
Treatment of murine cryptosporidiosis with anticyryptosporidial
immune rat bile. Am. J. Trop. Med. Hyg. 50, 112–119.
Appleby, P., and Catty, D. (1983). Transmission of immunoglobulin to
foetal and neonatal mice. J. Reprod. Immunol. 5, 203–213.
Arango-Jaramillo, S., Wisseman, C.L., Jr., and Azad, A.F. (1988).
Newborn rats in the murine typhus enzootic infection cycle:
studies on translacental infection and passively acquired
maternal antiticlerical antibodies. Am. J. Trop. Med. Hyg. 39,
391–397.
Arnold, R.E. (1982). Treatment of rattlesnake bites. In Rattlesnake
Venoms: Their Actions and Treatment (ed. A.T. Tu), 315–338. New
York: Marcel Dekker.
Baker, C.J., Rench, M.A., Edwards, M.S., Carpenter, R.J., Hays, B.M.,
and Kasper, D.L. (1988). Immunization of pregnant women with
a polysaccharide vaccine of group B streptococcus. N. Engl.
J. Med. 319, 1180–1185.
Barber, W.H., and Small, P.A., Jr. (1978). Local and systemic immunity
to influenza infections in ferrets. Infect. Immun. 21, 221–228.
Barnes, G.L., Hewson, P.H., McLeBar, J.A., Doyle, L.W., Knoches,
A.M.L., Kilchen, W.H., and Bishop, R.F. (1982). A randomized
trial of oral gammaglobulin in low-birth weight infants infected
with rotavirus. Lancet 1, 1371–1373.
Barthold, S.W., Beck, D.S., and Smith, A.L. (1988). Mouse hepatitis
virus and host determinants of vertical transmission and mater-
nally-derived passive immunity in mice. Arch. Virol. 100,
171–183.
Bertone, J.J., Jones, R.L., and Curtis, C.R. (1988). Evaluation of a test
kit for determination of serum immunoglobulin G concentration
in foals. J. Vet. Intern. Med. 2, 181–183.
Bessen, D., and Fischetti, V.A. (1988). Passive acquired mucosal immu-
nity to group A streptococci by secretory immunoglobulin A.
J. Exp. Med. 167, 1945–1950.
Blandach, T.G., Czinn, S.J., Maurer, R., Thomas, W.D., Soman, G.,
and Nedrud, J.G. (1995). Urease-specific monoclonal antibodies pre-
vent Helicobacter felis infection in mice. Infect. Immun. 63,
1394–1399.
Bogstedt, A.K., Johansen, K., Hatta, H., Kim, M., Casswall, T.,
Svensson, L., and Hammarström, L. (1996). Passive immunity against
diarrhoea. Acta Paediatr. 85, 125–128.
Boli, E.H., and Saif, L.J. (1975). Passive immunity in transmissible gas-
troenteritis of swine: immunoglobulin characteristics of antibod-
ies in milk after inoculating virus by different routes. Infect.
Immun. 11, 23–32.
Burns, J.W., Siadat-Pajouh, M., Krishnaney, A.A., and Greenberg, H.B.
(1996). Protective effect of rotavirus VP6-specific IgA mono-
clonal antibodies that lack neutralizing activity. Science 272,
104–107.
Busse, P.J., Razvi, S., and Cunningham-Rundles, C. (2002). Efficacy of
intravenous immunoglobulin in the prevention of pneumonia in
patients with common variable immunodeficiency. J. Allergy Clin.
Immunol. 109, 1001–1004.
Buthala, D.A., and Damiano, B.S. (1970). Studies on Coxsackie A-21
(COE) virus-infected volunteers: Effect of local therapy with
 gamma globulin. Ann. N.Y. Acad. Sci. 173, 794.
Butler, J.E., Fremy, V.L., Whipp, S.C., Wilson, R.A., and Koertge, T.E.
(1986). The metabolism and transport of bovine serum Siga.
Comp. Immunol. Microbiol. Infect. Dis. 9, 303–315.
Centers for Disease Control. (1991a). Babies prevention–United States:
recommenda
recommendations of the Immunization Practices Advisory
Committee (ACIP). MMWR Morb. Mortal. Weekly Rep. 40
(RR-3), 7–8.
Centers for Disease Control (1991b). Diphtheria, tetanus, and pertussis:,
recommendations for vaccine use and other preventative mea-
recommendations of the Immunization Practices Advisory
Committee (ACIP). MMWR Morb. Mortal. Weekly Rep. 40
(RR-10), 21–22.
Challacombe, S.J., Russell, M.W., Hawke, J.E., Bergmeier, L.A., and
Lehner, F. (1978). Passage of immunoglobulins from plasma to
the oral cavity in thesis monkeys. Immunology 35, 923–931.
Cotter, T.W., Meng, Q., Shen, Z.L., Zhang, Y.X., Su, H., and Caldwell,
H.D. (1995). Protective efficacy of major outer membrane pro-
tin-specific immunoglobulin A (IgA) and IgG monoclonal anti-
bodies in a murine model of Helamia trachomatis genital tract
infection. Infect. Immun. 63, 4704–4714.
Crouch, C.F. (1987). Vaccination against enteric rotavirus and coronaviruses
in cattle and pigs: enhancement of lactogenic immunity. Vaccine
3, 284–291.
Czinn, S.J., Cai, A., and Nedrud, J.G. (1993). Protection of germ-free
mice from infection by Helicobacter felis after active oral or passive
IgA immunization. Vaccine 11, 637–642.
Dahlgren, U., Ahlstedt, S., Hedman, L., Wadsworth, C., and Hanson,
L.A. (1981). Dimeric IgA in the rat is transferred from serum
into bile but not into milk. Scand. J. Immunol. 14, 95–98.
Delacrow, D.L., Hodgson, H.J., McPherson, A., Dive, C., and Vaerman,
J.P. (1982). Selective transport of polymeric immunoglobulin A
in bile. Quantitative relationships of monomeric and polymeric
immunoglobulin A, immunoglobulin M, and other proteins in
serum, bile, and saliva. J. Clin. Invest. 70, 230–241.
Delacrow, D.L., Malburyn, G.N., and Vaerman, J.P. (1985). Hepatobiliary
transport of plasma IgA in the mouse: contribution to the clearance of intravascular IgA. Eur. J. Immunol. 15,
893–899.

Mucosal Immunity and Infection
Chapter 46 Passive Immunization: Systemic and Mucosal

Dooley, J.S., Potter, B.J., Thomas, H.C., and Sherlock, S. (1982). A comparative study of the biliary secretion of human dimeric and monomeric IgA in the rat and in man. *Hepatology* 2, 323–327.

Ellis, T.H., Carman, W.E., and Wilcox, G.E. (1986). The effect of colostrum-derived antibody on neonatal transmission of caprine arthritis-encephalitis virus infection. *Aust. Vet. J.* 63, 242–245.

Enriquez, F.J., and Riggs, M.W. (1998). Role of immunoglobulin A on the transfer of foot and mouth disease antibodies from the sow to her piglets. *J. Hyg. Lond.* 93, 123–131.

Fruchtman, M.H., Mauceri, A.A., Migley, F.M., and Waldman, R.H. (1972). Aerosol administration of human gamma globulin as prophylaxis against influenza virus challenge. *Clin. Med.* 79, 17.

Gardner, M.M. (1976). Localization of rabbit gamma globulins in the mouse visceral yolk sac placenta. *Anat. Rec.* 184, 665–677.

Goldman, A.S., Ham-Pong, A.J., and Goldblum, R.M. (1985). Host defenses: development and maternal contributions. *Adv. Pediatr.* 32, 71–100.

Griffiss, J.M., and Goroff, D.K. (1983). IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. *J. Immunol.* 130, 2882–2885.

Guarino, A., Cabani, R.B., Russo, S., Albano, F., Canani, M.B., Ruggeri, F.M., Donelli, G., and Rubino, A. (1994). Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. *Pediatrics* 93, 12–16.

Halsey, J.F., Mitchell, C.S., and McKenzie, S.J. (1983). The origin of secretory IgA in milk: a shift during lactation from a serum origin to local synthesis in the mammary gland. *Ann. N.Y. Acad. Sci.* 409, 452–459.

Hammerberg, B., Musoke, A.J., Williams, J.F., and Leid, R.W. (1977). Uptake of colostral immunoglobulins by the suckling rat. *Lab. Anim. Sci.* 27, 50–53.

Hammarström, L., Gardulf, A., Hammarström, V., Janson, A., Lindberg, K., and Edvard Smith, C.I. (1994). Systemic and topical immunoglobulin treatment in immunocompromised patients. *Immun. Rev.* 139, 43–70.

Hammarström, V., Smith, C.I.E., and Hammarström, L. (1993). Oral immunoglobulin treatment in *Campylobacter jejuni* enteritis. *Lancet* 341, 1036.

Harriman, R.G., Gouge, M., Rogers, P., Finegold, M., Pacheco, S., Bradley, A., Zhang, Y., and Mbwauite, I.N. (1999). Targeted deletion of the IgA constant region in mice leads to IgA deficiency with alterations in expression of other Ig isotypes. *J. Immunol.* 162, 2521–2529.

Helikin, T., Ruohola, A., Ruskanen, O., Wari, S.M., Uhart, M., and Hammarström, L. (1998). Intraanally administered immunoglobulin for the prevention of rhinitis in children. *Pediatr. Infect. Dis. J.* 17, 367–372.

Heiman, H.S., and Weisman, L.E. (1989). Transplacental or enteral transfer of maternal immunization-induced antibody protects suckling rats from type III group B streptococcal infection. *Pediatr. Res.* 26, 629–632.

Heremans, J.F. (1974). Immunoglobulin A. In *The Antigens*. Vol. 2. (ed. M. Sela). 365–522. London: Academic Press.

Hjel, K., Grauballe, P.C., Nielsen, O.H., Schiotz, P.O., and Kihlström, P.A. (1985). Rotavirus antibodies in the mother and her breast-fed infant. *J. Pediatr. Gastroenterol. Nutr.* 4, 414–420.

Hockel, M., and Kaufmann, R. (1986). Placental transfer of class G immunoglobulins treated with beta-propiolactone (beta-PL) for intravenous application—a case report. *J. Perinat. Med.* 14, 205–208.

Jaz, M.K., Sabara, M.I., Frenchick, P.J., and Babiuk, L.A. (1987). Effect of different routes of immunization with bovine rotavirus on lactogenic antibody response in mice. *Antiviral Res.* 8, 283–297.

Jakoi, E.R., Cambier, J., and Saslow, S. (1985). Transepithelial transport of maternal antibody: purification of IgG receptor from newborn rat intestine. *J. Immunol.* 135, 3360–3364.

Johansen, F.-E., Pelka, M., Norderhaug, I.N., Haneberg, B., Hietala, M.A., Krajić, P., Betsholtz, C., and Brandzaeg, P. (1999). Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. *J. Exp. Med.* 190, 915–922.

Jollie, W.P. (1985). Immunocytochemical localization of antibody during placental transmission of immunity in rats. *J. Reprod. Immunol.* 7, 261–274.

Junghans, R.P., and Anderson, C.L. (1996). The protection receptor for IgG catalobism is the beta2-microglobulin-containing neonatal intestinal transport receptor. *Proc. Natl. Acad. Sci. U.S.A.* 93, 5512–5516.

Kenny, J.F., Boesman, M.I., and Michaels, R.H. (1967). Bacterial and viral coproantibodies in breast-fed infants. *Pediatrics* 39, 202–213.

Koerger, T.E., and Butler, J.E. (1986a). Dimeric mouse IgA is transported into rat bile five times more rapidly than into mouse bile. *Scand. J. Immunol.* 24, 567–574.

Koerger, T.E., and Butler, J.E. (1986b). Dimeric M315 is transported into mouse and rat milk in a degraded form. *Mol. Immunol.* 23, 839–845.

Kohl, S., and Loo, L.S. (1984). The relative role of transplacental and milk immune transfer in protection against lethal neonatal herpes simplex virus infection in mice. *J. Infect. Dis.* 149, 38–42.

Koutras, A.K., and Vigorita, V.J. (1989).08. Dimeric secretory immunoglobulin A in breast milk versus formula feeding in early infancy. *J. Pediatr. Gastroenterol. Nutr.* 9, 58–61.

Kris, R.M., Yetter, R.A., Cogilano, R., Ramphil, R., and Small, P.A., Jr. (1988). Passive serum antibody causes temporary recovery from influenza virus infection of the nose, trachea, and lung of nude mice. *Immunology* 63, 349–353.

Kubagawa, H., Bertoli, L.F., Barton, J.C., Koopman, W.J., Mestecy, J., and Cooper, M.D. (1987). Analysis of paraprotein transport into the saliva by using anti-idiotype antibodies. *J. Immunol.* 138, 435–439.

Kuroki, M., Ohta, M., Isemori, Y., Peralta, R.C., Yokoyama, H., and Kodama, Y. (1994). Passive protection against bovine rotavirus in calves by specific immunoglobulins from chicken egg yolk. *Arch. Virol.* 138, 143–148.

Leach, L., Eaton, B.M., Fidler, J.A., and Contractor, S.F. (1990). Uptake and intracellular routing of peroxidase-conjugated immunoglobulin-G by the perfused human placenta. *Cell Tissue Res.* 261, 383–388.

Leher, H., Zaragoza, F., Taherzadeh, S., Alizad eh, H., and Niederkorn, J. Y. (1999). Monoclonal IgA antibodies protect against *Ascaris lumbricoides* keratitis. *Exp. Eye Res.* 69, 75–84.

Lennon, J.L., and Black, F.I. (1986). Maternally derived measles immunity in era of vaccine-protected mothers. *J. Pediatr.* 108, 671–676.

Lindberg, K., and Berglund, B. (1996). Effect of treatment with nasal IgA on the incidence of infectious disease in world-class canoeists. *Int. J. Sports Med.* 17, 235–238.

Lindberg, K., Samuelson, A., Rynnel-Dagöö, B., Smith, C.I.E., and Hammarström, L. (1993). Nasal administration of IgA to individuals with hypogamma-globulinemia. *Scand. J. Infect. Dis.* 25, 395.

Lindbl, E. (1975). Increased resistance of immunoglobulin dimers to proteolytic degradation after binding of secreoty component. *J. Immunol.* 114, 284–286.

Loosli, C.G., Hamre, D., and Berlin, B.S. (1953). Airborne influenza virus A infections in immunized animals. *Trans. Assoc. Am. Phys.* 66, 222–230.

Ma, J. K., Hikmat, B. Y., Wycoff, K., Vine, N. D., Chargelegue, D., Yu, L., Hein, M. I., and Lehner, T. (1998). Characterization of a...
recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat. Med. 4, 601–606.

Maxson, R.T., Johnson, D.D., Jackson, R.J., and Smith, S.D. (1996). The protective role of enteral IgA supplementation in neonatal gut-origin sepsis. Ann. N.Y. Acad. Sci. 778, 405–407.

Mazanec, M.B., Lamm, M.E., Lyn, D., Portner, A., and Nedrud, J.G. (1987). Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. J. Virol. 61, 2624–2626.

Mazanec, M.B., Nedrud, J.G., and Lamm, M.E. (1987). Lamunogglubom A monoclonal antibodies protect against Sendai virus. J. Virol. 61, 2624–2626.

Mazanec, M.B., Nedrud, J.G., Liang, X., and Lamm, M.E. (1989). Transport of serum IgA into murine respiratory secretions and its implications for immunization strategies. J. Immunol. 142, 4275–4281.

Mbawule, J.K., Pacheo, A., Cucina, C.L., Switzer, K.C., Zhang, Y., and Harriman, G.R. (1999). Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J. Immunol. 162, 2530–2537.

McGuire, T.C., Poppie, M.J., and Banks, K.L. (1975). Hypogammaglobulinemia predisposing to infection in foals. J. Am. Vet. Med. Assoc. 166, 71–75.

McGuire, T.C., Poppie, M.J., and Banks, K.L. (1976). Failure of colostral immunoglobulin transfer in calves dying from infectious disease. J. Am. Vet. Med. Assoc. 169, 713–718.

Mestecy, J., and McGhee, J.R. (1987). Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv. Immunol. 40, 153–245.

Michalek, S.M., and McGhee, J.R. (1977). Effective immunity to dental caries: passive transfer to rats of antibodies to Streptococcus mutans elicits protection. Infect. Immun. 17, 644–650.

Michalek, S.M., Gregory, R.L., Harmon, C.C., Katz, J., Richardson, G.J., Hilton, T., Fillier, S.J., and McGhee, J.R. (1987). Protection of gnotobiotic rats against dental caries by passive immunization with bovine milk antibodies to Streptococcus mutans. Infect. Immun. 55, 2341–2347.

Michetti, P., Mahalanabis, D., Ashraf, H., Uicomb, L., Eeckels, R., and Mitra, A.K. (1995). Immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine 15, 575–582.

Palladino, G., Mozdzanowska, K., Washko, G., and Gerhardt, W. (1995). Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 69, 7055–7062.

Philapoin, A., Kaufman, M., Michtich, P., Cavaillon, J.M., Huereur, M., Sansonetti, P., and Kraehenbuhl, J.P. (1995). Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis. J. Exp. Med. 182, 769–778.

Prentice, A. (1987). Breast feeding increases concentrations of IgA in infants’ urine. Arch. Dis. Child. 62, 792–795.

Rahman, M.M., Yamauchi, M., Hanada, N., Nishikawa, K., and Morishima, T. (1987). Local production of rotavirus specific IgA in breast tissue and transfer to neonates. Arch. Dis. Child. 62, 401–405.

Rampal, R., Cogliano, R.C., Shands, J.W., Jr., and Small, P.A., Jr. (1979). Serum antibody prevents lethal murine influenza pneumonitis but not trachitis. Infect. Immun. 25, 992–997.

Renegar, K.B., and Small, P.A., Jr. (1991a). Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 146, 1972–1978.

Renegar, K.B., and Small, P.A., Jr. (1991b). Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J. Virol. 65, 2146–2148.

Renegar, K.B., Kudsk, K.A., Dewitt, R.C., and King, B.K. (2001a). Impairment of mucosal immunity by parenteral nutrition: depressed nasotracheal influenza-specific secretory IgA levels and transport in parenterally fed mice. Ann. Surg. 235, 134–138.

Renegar, K.B., Johnson, C.D., Dewitt, R.C., King, B.K., Liu, J., Fukatsu, K., and Kudsk, K.A. (2001b). Impairment of mucosal immunity by total parenteral nutrition: requirement for IgA in murine nasotracheal anti-influenza immunity. J. Immunol. 166, 819–825.

Renegar, K.B., Small, P.A., Jr., Boykis, L., and Wright, P. (2004). Role of IgA vs. IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 173, 1978–1986.

Renegar, K.B., Menge, A.C., Small, P.A., Jr., and Mestecy, J. Influenza infection of the murine uterus: A model for the study of mucosal immunity in the female reproductive tract. Manuscript in preparation.

Russell, M.W., Brown, T.A., and Mestecy, J. (1982). Preferential transport of IgA and IgG-immune complexes into bile compared with other external secretions. Mol. Immunol. 19, 677–682.

Russell, M.W., Reinholdt, J., and Kilian, M. (1989). Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation. Eur. J. Immunol. 19, 2243–2249.

Scicchitano, R., Husband, A.J., and Cripps, A.W. (1984). Immunoglobulin-containing cells and the origin of immunoglobulins in the respiratory tract of sheep. Immunol. 52, 529–537.

Scicchitano, R., Sheldrake, R.F., and Husband, A.J. (1986). Origin of immunoglobulins in respiratory tract secretion and saliva of sheep. Immunol. 58, 315–321.

Sheldrake, R.F., Husband, A.J., Watson, D.L., and Cripps, A.W. (1984). Selective transport of secreted-derived IgA into mucosal secretions. J. Immunol. 132, 363–368.

Simister, N.E., and Mostov, K.E. (1989). An Fc receptor structurally related to MHC class I antigens. Nature 337, 184–187.

Simister, N., and Rees, A.R. (1983). Properties of immunoglobulin G-Fc receptors from neonatal rat intestinal brush borders. Ciba Found. Symp. 59, 273–286.

Sokens, D.J., Jeejeebhoy, K.N., Bazin, H., and Underdown, B.J. (1979). Identification of secretory component as an IgA receptor on rat hepatocytes. J. Exp. Med. 150, 1538–1548.

Steinmetz, I., Albrecht, F., Hausler, S., and Brenneke, B. (1994). Monoclonal IgA class-switch variants against bacterial surface antigens: molecular arrays and transport into murine respiratory secretions. Eur. J. Immunol. 24, 2855–2862.

Tamura, S., Funato, H., Honda, N., Kuroki, M., and Saito, S. (1991). Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur. J. Immunol. 21, 1337–1344.
Tizzard, I. (1987). Immunity in the fetus and newborn. In Veterinary Immunology—An Introduction (ed. I. Tizzard), 3rd ed., 171–184. Philadelphia: WB Saunders.

Tjellström, B., Stenhammar, L., Eriksson, S, and Magnusson, K.-E. (1993). Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 341, 701–702.

Tomasi, T.B., Jr. (1970). The structure and function of mucosal antibodies. Ann. Rev. Med. 21, 281–298.

Tsunemitsu, H., Shimizu, M., Hirai, T., Yonemichi, H., Kudo, T., Mori, K., and Onoe, S. (1989). Protection against bovine rotaviruses in newborn calves by continuous feeding of immune colostrum. Nippon Juigaku Zasshi 51, 300–308.

Tuboly, S., Bernath, S., Glavits, R., and Medveczky, I. (1988). Intestinal absorption of colostral lymphoid cells in newborn piglets. Vet. Immunol. Immunopathol. 20, 75–85.

Vaerman, J.P. (1973). Comparative immunochemistry of IgA. Res. Immunochim. Immunobiol. 3, 91.

Vaerman, J.P., and Delacroix, D.L. (1984). Role of the liver in the immunobiology of IgA in animals and humans. Contrib. Nephrol. 40, 17–31.

von Behring and Kitasato (1890). On the acquisition of immunity against diphtheria and tetanus in animals. Dtsch. Med. Wochenschr. 16, 1113–1114.

Waldman, T.A., and Strober, W. (1969). Metabolism of immunoglobulins. Progr. Allergy 13, 1–110.

Welzinc, R., Hsu, S.A., Mittler, E.S., Georgakopoulos, K., and Monath, T.P. (1994). Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob. Agents Chemother. 38, 2785–2791.

Welzinc, R., Traina-Dorge, V., Soike, K., Zhang, J.-Y., Mack, P., Soman, G., Drabik, G., and Monath, T.P. (1996). Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infections. J. Infect. Dis. 174, 256–261.

Wilson, R.A., and Jutila, J.W. (1976). Experimental neonatal colibacillosis in cows: immunoglobulin classes involved in protection. Infect. Immun. 13, 100–107.

Winner, L., III, Mack, J., Welzinc, R., Mekalanos, J.J., Kraehenbuhl, J.-P., and Neutra, M.R. (1991). New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection. Infect. Immun. 59, 977–982.

Zeitlin, L., Castle, P. E., Whaley, K. J., Moench, T. R., and Cone, R. A. (1998). Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina. J. Reprod. Immunol. 40, 93–101.

Zhang, Y., Pacheco, S., Acuna, C. L., Switzer, K. C., Wang, Y., Gilmore, X., Harriman, G. R., and Mbwuike, I. N. (2002). Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus. Immunology 105, 286–294.